Surgical Treatment of Symptomatic Neuroma "Stop Neuroma"
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02528266|
Recruitment Status : Completed
First Posted : August 19, 2015
Last Update Posted : June 13, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Neuroma||Device: Nerve Capping Device||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Open Non-randomized Clinical Investigation to Evaluate the Safety and Effectiveness of the Nerve Capping Device to Prevent Neuroma Formation After Traumatic Nerve Section|
|Actual Study Start Date :||January 2016|
|Actual Primary Completion Date :||March 30, 2018|
|Actual Study Completion Date :||March 30, 2018|
Experimental: Nerve Capping Device
Implant with the experimental device
Device: Nerve Capping Device
- Safety data (Serious adverse events ) [ Time Frame: 6 weeks ]Serious adverse events related to the investigation device as determine by independent expert.
- Effectiveness (VAS score) [ Time Frame: 6 weeks ]Pain caused by symptomatic end-neuroma: VAS score (0-100 / no pain - unbearable pain) at 6-week follow-up compared to score at baseline.
- Effectiveness (QuickDASH score) [ Time Frame: 6 weeks ]Pain caused by symptomatic end-neuroma: QuickDASH score (30 items scored 1-5) at 6-week follow-up compared to score at baseline.
- Effectiveness (Quantity and class of pain medication used) [ Time Frame: 6 weeks ]Quantity and class of pain medication used for the end-neuroma pain at 6-week follow-up compared to baseline
- Safety (Rate of serious adverse device effects) [ Time Frame: 3, 6 and 12 months ]
Rate of serious adverse device effects as determined by the physician and independent expert.
- Reduction of pain caused by symptomatic neuroma after 3 months, 6 months and 12 months following the procedure, as compared to pain before the procedure.
- Improvement of quality of life at 3 months, 6 months and 12 months follow-up, as compared to the quality of life before the procedure.
- ≤20% recurrence of symptomatic neuroma within 12 months.
- Reduction of pain medication used to treat neuroma pain at 3 months, 6 months and 12 months, as compared to the quantity pain medication used for the neuroma pain before the procedure.
- Effectiveness (VAS score) [ Time Frame: 3, 6, 12 months ]Pain caused by symptomatic end-neuroma: VAS score (0-100 / no pain - unbearable pain) compared to score at baseline.
- Effectiveness (QuickDASH score) [ Time Frame: 3, 6, 12 months ]Pain caused by symptomatic end-neuroma: QuickDASH score (30 items scored 1-5) compared to score at baseline.
- Effectiveness (DN4 score) [ Time Frame: 6 weeks, 3, 6, 12 months ]Pain caused by symptomatic end-neuroma: DN4 score (10 y/n items characterising pain) compared to score at baseline.
- Effectiveness (Elliot score) [ Time Frame: 6 weeks, 3, 6, 12 months ]Pain caused by symptomatic end-neuroma: Elliot score (5 items rated 0 (no pain) to 4 (pain intolerable)) compared to score at baseline.
- Effectiveness (Quantity and class of pain medication used) [ Time Frame: 3, 6, 12 months ]Quantity and class of pain medication used for the neuroma pain at 3, 6 and 12 months
- Rate of recurrence of symptomatic neuroma [ Time Frame: 12 months ]defined as daily pain combined with increased used of pain medication compared to baseline and no improvement in QuickDASH score, but pain is relieved with Xylocaine nerve block.
- Usability (User Device Handling Questionnaire) [ Time Frame: Day 0 ]Ease of placement of the device assessed via User Device Handling Questionnaire.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Subjects will be eligible according to the following criteria:
- Subjects who are able to provide a written informed consent prior to participating in the clinical investigation.
- Subjects who are > 18 years year old.
- Subjects with a diagnosis of symptomatic primary or secondary end-neuroma.
- Symptomatic neuroma located on the upper limb between the metacarpophalangeal (MCP) joints to shoulder.
- Symptomatic neuroma confirmed by pain relief following a 10min ±2min nerve block with Xylocaine (Lidocaine) - Pain relief defined as any reduction in VAS questionnaire score.
- Subjects with history of pain in the area of the end-neuroma for at least 6-months.
- Subjects with a positive Tinel's sign.
Subjects who meet any of the following criteria will be excluded from participation:
- Inability to comply with the clinical investigation follow-up or other clinical investigation requirements.
- Subjects who are pregnant or intend to become pregnant during the duration of the clinical investigation or subjects who are not using appropriate birth control.
- Subjects who have had historical radiotherapy in the area of the end-neuroma.
- Symptomatic neuroma located proximally from the shoulder or distally from MCP joints.
- Subjects not willing to follow post-surgery protocols (e.g. avoiding pressure on the implant zone).
- Subjects is involved in another pain study.
- Subjects who have a known allergy to anesthetic agent or bioresorbable copolyester Poly(68/32[15/85 D/L] Lactide-Ԑ-Caprolactone) (PLCL).
- Subjects with a symptomatic neuroma that underwent surgical treatment for pain management on two or more occasions.
- Insufficient soft tissue at the end-neuroma site to cover the investigational device.
- Immunosuppressed patients, or patients with planned immunosuppressive therapy within 12-month following the study procedure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02528266
|Strasbourg University Hospitals|
|Strasbourg, France, F-67493|
|Den Haag, Netherlands, 2545 CH|
|Albert Schweitzer Hospital|
|Dordrecht, Netherlands, 3318 AT|
|Groningen, Netherlands, 9713GZ|
|Martini Hospital Groningen|
|Groningen, Netherlands, 9728 NT|
|Lelystad, Netherlands, 8233AA|
|Maastricht, Netherlands, 6229 HX|
|Study Chair:||Betty IJmker, MSc||Polyganics BV|
|Responsible Party:||Polyganics BV|
|Other Study ID Numbers:||
|First Posted:||August 19, 2015 Key Record Dates|
|Last Update Posted:||June 13, 2018|
|Last Verified:||June 2018|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
Nerve Sheath Neoplasms
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type